Abstract： Objective： To explore the potential mechanism of Sanzi Yangqin Decoction for chronic bronchitis （CB） based on network pharmacology and molecular docking technology. Methods：The active components and targets of each herb in Sanzi Yangqin Decoction were screened by using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform （TCMSP） and the SwissTargetPrediction platform. Disease targets of CB were retrieved from the GeneCards database， the Online Mendelian Inheritance in Man （OMIM） database， and the Therapeutic Target Database （TTD）. The intersection of the active components of Sanzi Yangqin Decoction and the disease targets of CB was obtained to identify the common targets for the treatment of CB. A Venn diagram was created to visualize the intersection of medicine-disease targets. Cytoscape 3.9.1 software was used to construct a network diagram of the intersection targets for the active components of Sanzi Yangqin Decoction in the treatment of CB. A Protein-Protein Interaction （PPI） network was obtained from the STRING database，of which is used for PPT analysis，and Cytoscape 3.9.1 software was then used to screen the core targets of the PPI network. Gene Ontology （GO） functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes （KEGG） pathway enrichment analysis were performed using the DAVID database. Molecular docking verification was performed using AutoDockTools software between the five core active ingredients of Sanzi Yangqin Decoction and the five key targets for the treatment of CB with Sanzi Yangqin Decoction. Results： A total of 530 targets for the active ingredients in Sanzi Yangqin Decoction， 1 103 targets for CB， and 109 intersection targets for Sanzi Yangqin Decoction in the treatment of CB were obtained. The network diagram of the intersection targets showed that luteolin，11，14，17-trienoic acid methylester，chromone，β-sitosterol， and arachidonic acid were the core active ingredients of Sanzi Yangqin Decoction for CB treatment. PPI network analysis suggested that signal transducer and activator of transcription3 （STAT3）， phosphatidylinositol 3-kinase regulatory subunit aplha （PIK3R1）， cellular tumor antigen p53 （TP53）， proto-oncogene tyrosine protein kinase （SRC）， α -serine/threonine protein kinase （AKT1）， and phosphoinositide 3-kinase α （PIK3CA） were the core targets. GO functional enrichment analysis indicated that the active ingredients might exert their effects through various biological processes， including chemical reactions， cellular responses to chemical stimuli， apoptosis， receptor binding， and macromolecular complex binding. KEGG pathway enrichment analysis showed that the treatment of CB with Sanzi Yangqin Decoction is associated with multiple signaling pathways， including human cytomegalovirus infection， chemical carcinogenesis-receptor activation， and protein aggregate in cancer. Luteolin， 14，11，17-trienic acid methylester， and arachidonic acid， demonstrated good binding activity with key targets such as STAT3， PIK3R1， TP53， SRC， AKT1， and PIK3CA. Conclusion： Sanzi Yangqin Decoction may exert its therapeutic effects on CB through its main components like luteolin， 14，11，17-trienic acid methylester， and arachidonic acid， which act on targets like STAT3， PIK3R1， and SRC. These interactions influence multiple pathways， including human cytomegalovirus infection， chemical carcinogenesis-receptor activation， and protein aggregate in cancer， thereby contributing to the treatment of CB.